

1. Wiesenfarth, M. *et al.* Clinical and genetic features of amyotrophic lateral sclerosis patients with C9orf72 mutations. *Brain Commun.* **5**, fcad087 (2023).
2. Yilmaz, R. *et al.* Frequency of C9orf72 and SOD1 mutations in 302 sporadic ALS patients from three German ALS centers. *Amyotroph. Lateral Scler. Front. Degener.* **24**, 414–419 (2023).
3. Petri, S. *et al.* Guideline “Motor neuron diseases” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie). *Neurol. Res. Pr.* **5**, 25 (2023).
4. Meyer, T. *et al.* Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross-sectional multicenter study. *Eur. J. Neurol.* **30**, 1600–1610 (2023).
5. Meyer, T. *et al.* Remote digital assessment of amyotrophic lateral sclerosis functional rating scale – a multicenter observational study. *Amyotroph. Lateral Scler. Front. Degener.* **24**, 175–184 (2023).
6. Ruf, W. P. *et al.* Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis. *Brain Commun.* **5**, fcad152 (2023).
7. Maier, A. *et al.* ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale. *Neurol. Res. Pr.* **4**, 60 (2022).
8. Maier, A. *et al.* Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. *Sci. Rep.* **12**, 9657 (2022).
9. Grehl, T. Amyotrophe Lateralsklerose (ALS). *Neurol. up2date* **04**, 309–313 (2021).
10. Requardt, M. V., Görlich, D., Grehl, T. & Boentert, M. Clinical Determinants of Disease Progression in Amyotrophic Lateral Sclerosis—A Retrospective Cohort Study. *J. Clin. Med.* **10**, 1623 (2021).
11. Ferrea, S. *et al.* Cortical Thinning of Motor and Non-Motor Brain Regions Enables Diagnosis of Amyotrophic Lateral Sclerosis and Supports Distinction between Upper- and Lower-Motoneuron Phenotypes. *Biomedicines* **9**, 1195 (2021).
12. Dorst, J. *et al.* Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. *J. Neurol., Neurosurg. Psychiatry* **91**, 1007–1009 (2020).
13. Meyer, T. *et al.* Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. *J. Neurol., Neurosurg., Psychiatry* **91**, 783–785 (2020).
14. Ludolph, A. C. *et al.* Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. *Ann. Neurol.* **87**, 206–216 (2020).
15. Höffken, O. *et al.* Excitability in somatosensory cortex correlates with motoric impairment in amyotrophic lateral sclerosis. *Amyotroph. lateral Scler. Front. Degener.* **20**, 192–198 (2019).
16. Dorst, J. *et al.* Eine hochkalorische, fettreiche Nahrungsergänzung für ALS-Patienten: Ergebnisse einer multizentrischen, randomisierten, placebo-kontrollierten Studie im Deutschen Netzwerk für Motoneuronerkrankungen (LIPCAL-ALS-Studie). *24 Kongr. des Med.-Wiss. Beirates Dtsch. Ges. für Muskelkranke (DGM) eV* **38**, 290–291 (2019).

17. Dorst, J. *et al.* Prognostic factors in ALS: a comparison between Germany and China. *J. Neurol.* **266**, 1516–1525 (2019).
18. Lingor, P. *et al.* ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. *Front. Neurol.* **10**, 293 (2019).
19. Brenner, D. *et al.* Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. *Brain : a J. Neurol.* **142**, e67 (2019).
20. Funke, A. *et al.* Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. *Amyotroph. Lateral Scler. Front. Degener.* **19**, 342–350 (2018).
21. Müller, K. *et al.* Comprehensive analysis of the mutation spectrum in 301 German ALS families. *J. Neurol., Neurosurg. Psychiatry* **89**, 817–827 (2018).
22. Brenner, D. *et al.* Hot-spot KIF5A mutations cause familial ALS. *Brain* **141**, 688–697 (2018).
23. Ludolph, A. C. *et al.* Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. *Lancet Neurol.* **17**, 681–688 (2018).
24. Steinacker, P. *et al.* Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. *Amyotroph. Lateral Scler. Front. Degener.* **18**, 112–119 (2017).
25. Al-Chalabi, A. *et al.* July 2017 ENCALS statement on edaravone. *Amyotroph. lateral Scler. Front. Degener.* **18**, 471–474 (2017).
26. Stubendorff, B. *et al.* P 48 The time of the ALSFRS-R to decrease to 50% (D50) in a sigmoidal decay model sufficiently describes the complete disease course of amyotrophic lateral sclerosis. *Clin. Neurophysiol.* **128**, e353–e354 (2017).
27. Meininger, V. *et al.* Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol.* **16**, 208–216 (2017).
28. Nordin, A. *et al.* Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. *Amyotroph. Lateral Scler. Front. Degener.* **18**, 256–264 (2017).
29. Krüger, S. *et al.* Rare Variants in Neurodegeneration Associated Genes Revealed by Targeted Panel Sequencing in a German ALS Cohort. *Front. Mol. Neurosci.* **9**, 92 (2016).
30. Vercruysse, P. *et al.* Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. *Brain* **139**, 1106–1122 (2016).